US Bancorp
OCUL icon

US Bancorp’s Ocular Therapeutix OCUL Stock Holding History

US Bancorp’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39K Sell
447
-21
-4% -$190 ﹤0.01% 3694
2026
Q1 		$3.96K Buy
468
+214
+84% +$2.04K ﹤0.01% 3637
2025
Q4 		$3.08K Sell
254
-128
-34% -$1.55K ﹤0.01% 3667
2025
Q3 		$4.47K Sell
382
-21
-5% -$251 ﹤0.01% 3576
2025
Q2 		$3.74K Sell
403
-212
-34% -$1.66K ﹤0.01% 3720
2025
Q1 		$4.51K Buy
615
+298
+94% +$2.29K ﹤0.01% 3692
2024
Q4 		$2.71K Sell
317
-578
-65% -$5.64K ﹤0.01% 3802
2024
Q3 		$7.79K Sell
895
-1,460
-62% -$12K ﹤0.01% 3445
2024
Q2 		$16.1K Buy
+2,355
New +$14.5K ﹤0.01% 3147
2022
Q4 		– Sell
-3,011
Closed -$12K – 4239
2022
Q3 		$12K Buy
+3,011
New +$15.2K ﹤0.01% 3313
2022
Q1 		– Sell
-707
Closed -$5K – 4160
2021
Q4 		$5K Sell
707
-81,793
-99% -$635K ﹤0.01% 3654
2021
Q3 		$825K Sell
82,500
-274
-0.3% -$3.08K ﹤0.01% 1278
2021
Q2 		$1.17M Sell
82,774
-198
-0.2% -$3.01K ﹤0.01% 1124
2021
Q1 		$1.36M Hold
82,972
– – ﹤0.01% 1002
2020
Q4 		$1.72M Buy
+82,972
New +$1.23M ﹤0.01% 870
2017
Q4 		– Sell
-700
Closed -$4K – 3657
2017
Q3 		$4K Hold
700
– – ﹤0.01% 3306
2017
Q2 		$6K Hold
700
– – ﹤0.01% 3171
2017
Q1 		$6K Hold
700
– – ﹤0.01% 3164
2016
Q4 		$6K Sell
700
-250
-26% -$1.94K ﹤0.01% 3153
2016
Q3 		$7K Buy
950
+250
+36% +$1.52K ﹤0.01% 3085
2016
Q2 		$3K Hold
700
– – ﹤0.01% 3314
2016
Q1 		$7K Hold
700
– – ﹤0.01% 3083
2015
Q4 		$7K Buy
+700
New +$7.56K ﹤0.01% 3144

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

US Bancorp's OCUL Position: Q2 2026 in Review

US Bancorp reduced its Ocular Therapeutix (OCUL) stake by 4.5% in Q2 2026, selling an estimated $190 and leaving 447 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #3694.

US Bancorp first reported a position in OCUL in Q4 2015 and has held it in 23 quarters since. The position peaked at $1.72M in Q4 2020. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • US Bancorp held 447 shares of Ocular Therapeutix worth $4.39K as of Q2 2026.
  • US Bancorp sold 21 Ocular Therapeutix shares in Q2 2026, an estimated $190.
  • Ocular Therapeutix made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3694 holding.
  • US Bancorp first reported a position in Ocular Therapeutix in Q4 2015 and has held it in 23 quarters since.
  • US Bancorp's Ocular Therapeutix position peaked at $1.72M in Q4 2020.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.